Innate Pharma SA announced that Mondher Mahjoubi has resigned from his position as Chief Executive Officer (CEO) and Chairman of the Executive Board of the Company, effective as of January 2024, to pursue a senior level opportunity at a large pharmaceutical company. Hervé Brailly, Innate Pharma?s current Chairman of the Supervisory Board, former CEO and co-founder is appointed as interim CEO and Chairman of the Executive Board while a permanent successor is sought.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.59 EUR | -1.52% | -5.47% | -1.15% |
May. 24 | Innate Pharma: five abstracts selected for ASCO | CF |
May. 14 | Transcript : Innate Pharma S.A., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.15% | 231M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+36.92% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- IPH Stock
- News Innate Pharma
- Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024